Influence of CYP2D6 metabolizer status on ondansetron efficacy in pediatric patients undergoing hematopoietic stem cell transplantation: A case series

• Main Authors: Andrea Edwards (Author), Ashley Teusink‐Cross (Author), Lisa J. Martin (Author), Cynthia A. Prows (Author), Parinda A. Mehta (Author), Laura B. Ramsey (Author)
• Format: Book
• Published: Wiley, 2022-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Chemotherapy‐induced nausea and vomiting (CINV) is commonly experienced by patients receiving antineoplastic agents prior to hemopoietic stem cell transplant (HSCT). Ondansetron, a 5‐HT3 antagonist metabolized by CYP2D6, is an antiemetic prescribed to treat short‐term CINV, but some patient...